Ms. Ivana Maric reports
AVICANNA COMPLETES COMMERCIAL EXPORT OF CBD ISOLATE AND CBD FULL SPECTRUM PSYCHOACTIVE DERIVATIVES FROM COLOMBIA TO CHILE
Avicanna Inc., through its majority-owned Colombian subsidiary, Santa Marta Golden Hemp SAS (SMGH), has completed a commercial export of CBD (cannabidiol) Isolate and CBD full-spectrum psychoactive cannabis resin to a leading Chilean homeopathic and naturopathic pharmaceutical company.
The cannabis derivatives, branded as Aureus, are cultivated, extracted and manufactured by SMGH. In addition, for Avicanna's global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC (tetrahydrocannabinol) and rare cannabinoids such as CBG (cannabigerol) in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of a continuing relationship with an established homeopathic Chilean company.
To the knowledge of the company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
Avicanna's supply chain business units are based in Santa Marta, Colombia, and are primarily dedicated to providing a consistent source of cannabinoid raw materials for Avicanna's current commercial products and pharmaceutical pipeline for the global marketplace.
Additionally, under the Aureus brand, standardized cannabis extracts and feminized seeds are made available to cultivation, cosmetic and pharmaceutical partners around the world. Aureus branded products are cultivated, extracted and manufactured by Avicanna's subsidiaries in Colombia where they benefit from optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically and sustainably and include a range of extracts of CBD, THC and rare cannabinoids such as CBG. Avicanna's supply chain business also benefits from federally regulated legislation in Colombia where the company is well positioned to be a global supplier of the less-competitive psychoactive extracts including CBD and THC crude oil to meet the growing global demand.
About Avicanna Inc.
Avicanna is a commercial-stage Canadian biopharmaceutical company and an established leader in cannabinoid research, development and evidence-based products for the global consumer, medical and pharmaceutical market segments. Avicanna conducts its research in Canada including its research and devleopment headquarters in the Johnson & Johnson Innovation Centre, JLABS at Toronto, Canada, located in the MaRS discovery district, and in collaboration with leading Canadian academic and medical institutions. Avicanna has established an industry leading scientific platform including advanced R&D and clinical development which has led to the commercialization of over 20 products across four main market segments:
RHO Phyto: these medical and wellness products are an advanced line of pharmaceutical-grade cannabis products containing varying ratios of CBD and THC. The product portfolio contains a full formulary of products including oral, sublingual, topical and transdermal deliveries that have controlled dosing, enhanced absorption and stability studies supported by preclinical data. These products are developed using pharmaceutical drug development processes and are supported with preclinical data. The advanced formulary is marketed with consumer, patient and medical community education and training;
- Pura H&W: these registered, clinically tested cosmetic products include a portfolio of functional CBD consumer derma-cosmetic and topical products;
- Aureus: as a part of Avicanna's vertical integration based out of Santa Marta, Colombia, its supply chain business units are primarily dedicated to providing consistent source of cannabinoid raw materials for Avicanna and its global partner's food, cosmetic, medical and pharmaceutical needs. Aureus branded products are cultivated, extracted and manufactured by Avicanna's subsidiaries in Colombia where they benefit from optimal environmental conditions to produce cannabinoid active pharmaceutical ingredients economically, organically and sustainably and include a range of CBD, THC and rare cannabinoids such as CBG extracts and standardized seeds. The company is well positioned to be a global supplier of cannabinoid raw materials demand and has already successfully exported its products to over 10 countries in four continents;
- Pharmaceutical pipeline: leveraging from the company's scientific platform, vertical integration, and real-world evidence, Avicanna has established a pipeline of indication specific cannabinoid-based drug candidates that are in various stages of clinical development and commercialization. Avicanna's drug candidates are in the preclinical stage and are dedicated to providing solutions for unmet medical needs in the areas of dermatology, chronic pain and various neurological disorders.
We seek Safe Harbor.
© 2022 Canjex Publishing Ltd. All rights reserved.